Researching Safety and Cost-Effectiveness in the Life Cycle of Nanomedicine

Journal of Law & Medicine, Vol. 15, 2007

8 Pages Posted: 22 May 2009

See all articles by Thomas Alured Faunce

Thomas Alured Faunce

Australian National University

Kathy Shats

affiliation not provided to SSRN

Date Written: May 22, 2007

Abstract

Nanotechnology is rapidly emerging as a transformational influence on many industry sectors. This is particularly true of medicines and medical devices. This article argues that, as policy interest in devising an appropriate regulatory framework for nanotherapeutics escalates, it will be important for public health to ensure that a broad life-cycle approach to both safety and cost-effectiveness is adopted. It charts some of the most important issues likely to be faced and begins to map how they can best be addressed.

Keywords: Nanotechnology, safety, cost-effectiveness, drug regulation, nanomedicine

Suggested Citation

Faunce, Thomas Alured and Shats, Kathy, Researching Safety and Cost-Effectiveness in the Life Cycle of Nanomedicine (May 22, 2007). Journal of Law & Medicine, Vol. 15, 2007. Available at SSRN: https://ssrn.com/abstract=1408547

Thomas Alured Faunce

Australian National University ( email )

Canberra, Australian Capital Territory 0200
Australia
61 2 61253563 (Phone)

Kathy Shats (Contact Author)

affiliation not provided to SSRN

Register to save articles to
your library

Register

Paper statistics

Downloads
179
Abstract Views
912
rank
167,123
PlumX Metrics